KBC Securities - Amoeba SA (AMEBA) Amoéba Obtaining market authorisation in US for its AXPERA biocontrol solution

Report

KBC Securities

Guy Sips

Amoéba Obtaining market authorisation in US for its AXPERA biocontrol solution

We welcome Amoéba's first two biocontrol fungicides, AXPERA NOA and AXPERA GREEN, received approval from the US Environmental Protection Agency (US EPA) for the first crops targeted by Amoéba. Amoéba also indicated it is progressing in line with its strategic plan to begin marketing its biocontrol solution in Europe and the US in 2026.

Amoéba announced that it has received regulatory approval from the US Environmental Protection Agency (EPA) to market in the US its biocontrol products AXPERA NOA and AXPERA GREEN, based on the lysate of Willaertia magna C2c Maky.

We look forward to the commercial launch of Amoéba AXPERA products and maintain our Buy rating and € 1.5 Target Price.

17/10/2025 1 EN

Underlying

Amoeba SA

Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.

See profile

FR0011051598 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Amoéba Setting up Green 4 Agro, structuring its activities in biocontrol

Amoéba takes a further step in the structuring of its activities in the area of biocontrol, confirming its ambition to become a key player in the agroecological transition by setting up Green 4 Agro, its subsidiary dedicated to the commercialisation and development of its biocontrol and biostimulant solutions. As a reminder, commercial operations will begin in 2026 with the distribution of its AXPERA biocontrol solution for vineyards and vegetable crops, through its first partner, Koppert. Green 4 Agro is wholly owned by Amoéba. This development will enable them to set up a specific organisat...

October 16, 2025 October 16, 2025 1 EN

KBC Securities

Amoéba Now full speed ahead to commercial launch of its biocontrol solution in ‘26

First-half result numbers overshadowed by the various milestones achieved over the past two years by its biocontrol solution (with final approval of the active substance by the European Commission and the signing of a strategic distribution agreement with Koppert) now enables them to launch its commercialisation in 2026. The US EPA (Environmental Protection Agency) decision on the application for federal marketing authorisation in the US for AXPERA, which has been delayed for reasons beyond Amoéba's own control, is expected in 1Q26. We also welcome the interest in its cosmetic ingredient, bo...

October 10, 2025 October 10, 2025 1 EN

Warehouses De Pauw Conference call feedback, confident on execution

The tone in the call is cautious optimistic on the targets of the Blend27 program. The company stays focused on its 5 countries. In The Netherlands it is slow due to grid limitations. In France they have established a position and work on extending it. In Germany, prices and opportunities in the right regions have not occurred. Romania has just announced a development and acquired 400k sqm land. In Belgium, the Amazon €1bn will be spread over multiple investments and WDP is looking at the Audi approx. 60Ha site in Vorst (BXL). WDP repeated it has enough auto-finance, stock dividend and CiK pot...

15h / 55m 15h / 55m 1 EN

Lynn Hautekeete

Lynn Hautekeete

Basic-Fit 3Q25 trading update: total members already ahead of FY25 CSS

This morning, Basic-Fit published its 3Q25 trading update, showing strong Q3 member growth of +218k vs +110k last year (+95% YoY), despite a -54% YoY decline in club openings. Total members reached 4.73m, already ahead of the FY25 CSS target of 4.64m and our 4.69m (street high). At this pace, 4.8m by year-end looks achievable (+50k in 4Q24). Revenue was in line at €1.034bn vs €1.024bn KBCSe (+16% YoY), but average revenue per member came in soft at €24.60 (-0.5% QoQ). While flattish yield in high-ingrowth quarters (1Q/3Q) is seasonal, the drop may reflect either weaker premium uptake or higher...

19h / 32m 19h / 32m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Amoéba Obtaining market authorisation in US for its AXPERA biocontrol solution

We are a financial services provider for several types of professional clients, each with distinct needs.

Amoéba Setting up Green 4 Agro, structuring its activities in biocontrol

Amoéba Now full speed ahead to commercial launch of its biocontrol solution in ‘26

Warehouses De Pauw Conference call feedback, confident on execution

Basic-Fit 3Q25 trading update: total members already ahead of FY25 CSS

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe